Live feed07:00:00·36dPRReleasevia QuantisnowEditas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 InterferenceByQuantisnow·Wall Street's wire, on your screen.EDIT· Editas Medicine Inc.Health Care
